Shots:
The NICE has issued FAD recommending Beovu as a treatment option for use on the NHS for visual impairment due to DMO. Beovu’s recommended dosage of 6mg was administered by inj. q6w for the first 5 doses
The recommendation was based on the P-III (KESTREL) & (KITE) trials for brolucizumab vs aflibercept. The results showed an improvement in visual impairment & has the potential for fluid resolution & minimize treatment burden, patients with brolucizumab & aflibercept were treated on 12wk. & 8wk. intervals in the 1st yr., following the loading phase, disease activity moved to q8w
Additionally, ~50% of patients (55.1% in KESTREL & 50.3% in KITE) remained on a 12wk. dosing interval @1yr.
Ref: Novartis | Image: Novartis
